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Abstract Loci contributing to complex disease have been
identified by focusing on genome-wide scans utilising non-
synonymous single nucleotide polymorphisms (nsSNPs).
We employed Illumina’s HNS12 BeadChip (13,917 high-
value SNPs) which was specifically designed to capture
nsSNPs and ideally complements more dense genome-wide
association studies that fail to consider many of these
putatively functional variants. The HNS12 panel also
includes 870 tag SNPs covering the major histocompati-
bility region. All individuals genotyped in this study were
Caucasians with (cases) and without (controls) diabetic
nephropathy. About 449 individuals with type 2 diabetes
(203 cases, 246 controls) were genotyped in the initial
study. 1,467 individuals with type 1 diabetes (718 cases,
749 controls) were genotyped in the follow up study.
11,152 SNPs were successfully analysed and ranked for
association with diabetic nephropathy based on signifi-
cance (P) values. The top ranked 32 SNPs were subse-
quently genotyped using MassARRAY iPLEX
TM
and
TaqMan technologies to investigate association of these
polymorphisms with nephropathy in individuals with type
1 diabetes. The top ranked nsSNP, rs1543547 (P = 10-5),
is located in RAET1L, a major histocompatibility class I-
related gene at 6q25.1. Of particular interest, multiple
nsSNPs within the top ranked (0.2%) SNPs are within
several plausible candidate genes for nephropathy on
3q21.3 and 6p21.3.
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Introduction
Diabetic nephropathy is the leading cause of end stage
renal disease (ESRD), accounting for 22% of incident
patients with ESRD in the UK (Ansell et al. 2008) and 44%
in USA (USRDS 2008). There is a genetic predisposition
to diabetic nephropathy (Savage et al. 2007), although
refined genetic loci in White individuals have not yet
been convincingly confirmed across multiple populations
(McKnight et al. 2009a).
Non-synonymous single nucleotide polymorphisms
(nsSNPs) are distributed throughout the human genome
and are functionally relevant as they generate changes in
amino acid sequences for proteins. These nsSNPs are
important contributors to Mendelian and complex disease
phenotypes (Stitziel et al. 2004). Several studies have
successfully identified loci contributing to complex disease
by focusing on a genome-wide panel of nsSNPs (Smyth
et al. 2006; Hampe et al. 2007; WTCCC 2007). Although
our recent nsSNP study for diabetic nephropathy did not
identify variants that contribute significantly to the devel-
opment of diabetic nephropathy, this research was limited
in scope to only 1,111 nsSNPs in 1,021 genes (Savage et al.
2008).
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We report association data with diabetic nephropathy for
the HNS12 BeadChip (13,917 SNPs, Illumina Inc, San
Diego, CA, USA). This HNS12 panel resulted from an
in-depth focus on high-value, gene-centric variants and
ideally complements more dense genome-wide association
studies that fail to consider many of these variants (Evans
et al. 2008). This panel comprises more than 11,600
nsSNPs across the genome, and a dense set of 870 tag
SNPs across the major histocompatibility region (MHC).
Results
Clinical characteristics of recruited individuals are sum-
marised in Table 1. As expected with diabetic nephropa-
thy, higher blood pressure was observed for individuals in
the case group compared to controls. Individuals with type
2 diabetes had a mean age at diagnosis of diabetes 51 years
with mean duration of diabetes *15 years and similar
mean blood glucose values observed between case and
control groups. Average values for age at diagnosis, blood
glucose and body mass index were similar between cases
and controls with type 1 diabetes; both groups recorded a
relatively long mean duration of diabetes ([25 years).
A total of 2,765 SNPs were removed following bioinfor-
matic evaluation with 11,152 common (minor allele fre-
quency (MAF)[1%) SNPs successfully analysed (Fig. 1).
Six hundred and twenty-six SNPs were observed with sig-
nificance set to the five percent level (558 expected by
chance alone). About 242 SNPs were observed with Padjusted
\0.05 following permutation procedures to generate
empirical P values. SNPs were ranked for association with
diabetic nephropathy according to significance values and
the top ranked SNPs (Table 2) were selected for further
analysis.




Diego, CA, USA) and TaqMan (Applied Biosystems,
Foster City, CA, USA) technologies, in 1,467 individuals
with type 1 diabetes to investigate association with diabetic
nephropathy (Table 2). There was limited support for the
association between these SNPs and nephropathy in indi-
viduals with type 1 diabetes, however five SNPs revealed
P \ 0.05. Two of these SNPs (rs2076484, rs9380215,
P = 0.03) were located in 6p21.3.
Discussion
We have investigated 11,152 SNPs for association with dia-
betic nephropathy in individuals with type 2 diabetes recrui-
ted in Northern Ireland. Genotyping utilised a commercial
panel that has demonstrated highly accurate and reproducible
results, employing strict quality control parameters. Focusing









Age at diagnosis of diabetes (years) 51.6 ± 11.9 51.2 ± 9.7 14.8 ± 7.7 15.4 ± 8.0
Duration of diabetes (years) 15.2 ± 8.4 14.6 ± 6.4 34.5 ± 9.6 29.6 ± 9.1
a,b HbA1c (%) 10.2 ± 1.7 10.0 ± 1.4 8.8 ± 1.8 8.6 ± 1.5
BMI (kg/m2) 31.5 ± 6.6 30.7 ± 6.3 26.2 ± 5.0 26.1 ± 4.2
a Systolic BP (mmHg) 147 ± 20 140 ± 18 145 ± 21 125 ± 15
a Diastolic BP (mmHg) 76 ± 11 75 ± 10 82 ± 11 75 ± 8
Data are mean ± SD
a values are based on the average of the most recent three measurements for each individual
b DCCT (Diabetes Control and Complications Trial) aligned assay for hemoglobin A1c
1              11             3                                        7                  13        15            19    21   




Fig. 1 Log P values for each
SNP genotyped per
chromosome
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on nsSNPs is an attractive approach since less common
variants that may influence the risk of disease are directly
genotyped. None of the available genome-wide panels that
incorporate less than a million markers are optimised to
capture nsSNPs. For example, the Affymetrix 500 K chip
covers only 65% of the common nsSNPs (C5% MAF) and
24% of the rarer variants (\5% MAF) present on the HNS12
panel with an r2 [ 0.8 in the CEU population (Evans et al.
2008). The Ensembl genome browser contains 97,571
nsSNPs (www.ensembl.org, accessed 08/06/09) with a recent
report describing 133,505 coding SNPs in the human genome
(Reumers et al. 2008), although it should be noted that many
of these are not validated.
The top ranked SNPs, with respect to the adjusted P value,
were located in several biological and positional candidate
genes for diabetic nephropathy. rs1543547 demonstrated the
most evidence for association (adjusted Pgenotype = 4 9
10-5, Pallelic = 2 9 10
-5) based on comparisons of geno-
type and allele frequencies between cases and controls. This
SNP is located at 6q25.1 in the retinoic acid early transcript
1L gene. RAET1L spans approximately 5 kb and is a mem-
ber of the RAET1 family of MHC class I-related genes
located within the 180 kb cluster on chromosome 6q24.2-
6q25.3. Fine mapping would be complex as genes within this
region are very similar; for example, RAET1L reveals
approximately 97% identity with ULBP2 (Radosavljevic
et al. 2002). Information is sparse regarding the precise
function of this gene, however RAET1 genes encode gly-
coproteins that are anchored to the membrane via glyco-
sylphosphatidylinositol linkage (Radosavljevic et al. 2002).
Within the top ranked group, two nsSNPs were clustered
in the PLXND1 gene (rs2285372, rs2301572) at 3q21.3.
PLXND1 is expressed in human vascular endothelial cells
and is important for cardiovascular development (Gitler
et al. 2004). Eight of the top ranked 32 SNPs were located at
6p21.3 with three nsSNPs clustered within the ubiquitin D
(UBD) gene at 6p21.3 (rs2076487, rs2076486, rs2076484).
Several differences were observed when comparing our
genotype data to the higher-throughput information
recorded in dbSNP (www.ncbi.nlm.nih.gov/snp). Two
SNPs recorded in dbSNP as monomorphic (rs2076486,
rs2076848) were observed with minor allele frequencies of
3%. SNP rs1543547 was observed with 42% minor allele
frequency in our population compared to the 7% reported
for the HapMap CEU population. However, our results for
rs1543547 are similar to those reported by Perlegen
(ss24453248) where the T allele was observed at 46% in 24
samples from the Coriell Cell Repository that were pri-
marily of European descent. Linkage disequilibrium
(r2 [ 0.8) was observed between: rs2076486, rs2076484,
and rs2076487; rs2301572 and rs2285372; rs11755943 and
rs10452600. These relationships were exploited by only
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Ideally our results would be replicated in a larger, phe-
notypically similar group of individuals from the same
geographical region; such a collection is not available within
the British Isles. As there are shared pathophysiological
mechanisms contributing to the development of diabetic
kidney disease (for example, mesangial expansion and glo-
merular basement membrane thickening) in those with type 1
and type 2 diabetes (Caramori and Mauer 2003; Tsilibary
2003; Fioretto and Mauer 2007), we also genotyped the top
ranked variants to evaluate association with type 1 diabetes.
This larger case-control collection (n = 1,467) recruited
individuals from Ireland in conjunction with a UK multi-
centre collection (Genetics Of Kidneys in Diabetes UK) that
was specifically designed to investigate genetic risk factors
for diabetic nephropathy (McKnight et al. 2009b). A tag SNP
approach was taken where strong linkage disequilibrium was
observed, resulting in 28 SNPs actually genotyped in the
follow-up study. Although a strong association was not
observed with nephropathy in type 1 diabetes, two SNPs in
6p21.3 (rs2076484, rs9380215, P = 0.03) warrant further
investigation.
It is possible that the results from individuals with type 2
diabetes in Table 2 represent type 1 errors, or that genetic
variants associated with nephropathy in type 1 diabetes
may differ from those involved with nephropathy in type 2
diabetes. Robust quality control procedures were employed
and several SNPs in close proximity to each other were
associated with diabetic nephropathy in biologically plau-
sible genes. Replication and fine mapping in large popu-
lations of phenotypically similar individuals are required to
investigate further the top ranked variants.
Non-synonymous SNPs contribute to inter-individual
differences, the variation within biological networks,
genetic susceptibility to disease, and prediction of drug
responsiveness (Karchin et al. 2005). We have completed a
targeted genome-wide scan and revealed several novel
SNPs in genes that are worthy of further investigation;
validation studies are essential to confirm the importance of
these findings.
Methods
Ethical approval was obtained from the appropriate
Research Ethics Committee and all participants provided
written, informed consent prior to enrolment. All individ-
uals recruited for this study were White, with parents and
grandparents born in the British Isles.
Individuals with type 2 diabetes
About 449 individuals (203 cases, 246 controls) were
diagnosed with type 2 diabetes and genotyped in the
original panel. Type 2 diabetes was defined as current or
previous use of hypoglycaemic agents or diet without
recourse to insulin in the first year of diabetes diagnosis;
MODY patients were excluded. Cases with diabetic
nephropathy were defined as such if they had persistent
proteinuria with ([0.3 g protein/24 h or raised albumin-
creatinine ratio (ACR) [30 mg/mmol on at least two
occasions), or previously had levels of proteinuria consis-
tent with this case definition prior to commencement of
renin-angiotensin system blocking drugs. Cases with dia-
betic nephropathy may have had chronic renal failure
(eGFR \60 ml/min/1.73 m2) or end stage renal disease
(managed by dialysis or renal transplant). Importantly,
patient notes and previous consultant medical opinions
were scrutinised to exclude potential cases with non-dia-
betic nephropathy. The control group consisted of indi-
viduals with type 2 diabetes of at least 10 years duration
and who had no evidence of proteinuria or microalbu-
minuria on repeated testing. Individuals receiving ACE
inhibitors and/or angiotensin receptor blockers were
excluded from the control group; this helps to avoid mis-
classification of the control phenotype since anti-hyper-
tensive treatment may lower urinary albumin excretion.
Individuals with type 1 diabetes
This collection includes individuals recruited as part of the
Warren 3 and GoKinD UK resources (McKnight et al.,
2009b). All individuals were diagnosed with type 1 dia-
betes before 31 years of age. Individuals with nephropathy
had diabetes for at least 10 years before the onset of per-
sistent proteinuria ([0.5 g protein/24 h), hypertension
(blood pressure [135/85 mg Hg and/or treatment with
antihypertensive medication) and diabetic retinopathy.
Individuals recruited as controls had duration of diabetes of
at least 15 years, were not taking antihypertensive medi-
cation and did not demonstrate any evidence of renal dis-
ease. The presence of microalbuminuria (20–200 mcg/min)
or evidence of non-diabetic renal disease were exclusion
criteria for this collection.
Genotyping and data analysis
The commercially available Human NS12 BeadChip was
processed using the Infinium I Whole-Genome Geno-
typing Assay (Illumina Inc, San Diego, CA, USA,
www.illumina.com). This HNS12 panel contains 13,917
unique SNPs, developed from the targeted investigation of
high-value, gene-centric variants, and comprises more than
11,600 nsSNPs distributed across the genome together with
a dense set of 870 tag SNPs across the MHC region.
Genotyping of the HNS12 panel was conducted at
deCODE Genetics (Reykjavik, Iceland); further details
HUGO J (2009) 3:77–82 81
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regarding the assays are available from the authors. SNPs
with individual GenCall scores[0.25, call rates of at least
90% for both cases and controls, genotype distributions in
accordance with Hardy-Weinberg equilibrium, and minor
allele frequencies [1% were compared between case and
control groups. Comparison of cases and controls was
conducted using PLINK version 1.04 (Purcell et al. 2007;
McKnight et al. 2009b). Permutation procedures provide a
framework to adjust for multiple comparisons and empir-
ical P values were generated using the permutation pro-
cedure (genotype model) implemented in PLINK. A
quantile-quantile plot of observed chi-squared test statistics
against expected order statistics was used to assess possible
inflation of the chi-squared test statistics (Clayton et al.
2005). The current cytogenetic and sequence position on
each chromosome location was obtained from dbSNP build
129, GenBank genome build 36.3, along with amino acid
changes in associated genes.
Linkage disequilibrium was investigated for the top
ranked SNPs and tag SNPs identified (r2 [ 0.8) using
Haploview (Barrett et al. 2005; de Bakker et al. 2005).
Genotyping was performed for the top ranked variants in the
type 1 diabetic collection using iPLEX (Sequenom Com-
pact, San Diego, CA, USA) and TaqMan (7900HT, Applied
Biosystems, Warrington, UK) technologies. Cases and
controls were randomly arranged in 384-well plates with
uniquely positioned negative controls, duplicate samples
and four father-mother-proband trios providing experi-
mental quality control. As above, genotypic and allelic data
were compared for cases and controls using PLINK.
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